PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: CUSTOMER LANDSCAPE PART 07: MARKET SEGMENTATION BY TARGET Market segmentation by target Comparison by target CD19/CD3 - Market size and forecast 2018-2023 CD30/CD16A - Market size and forecast 2018-2023 Market opportunity by target PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Market trends PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Amgen Inc. Astella Pharma Inc. Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. Merus Regeneron Pharmaceuticals, Inc. PART 14: APPENDIX Research methodology List of abbreviations PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Bispecific antibodies for cancer under development Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Customer landscape Exhibit 19: Target - Market share 2018-2023 (%) Exhibit 20: Comparison by target Exhibit 21: CD19/CD3 - Market size and forecast 2018-2023 ($ millions) Exhibit 22: CD19/CD3 - Year-over-year growth 2019-2023 (%) Exhibit 23: CD30/CD16A - Market size and forecast 2018-2023 ($ millions) Exhibit 24: CD30/CD16A - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by target Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 31: Europe - Year-over-year growth 2019-2023 (%) Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Asia - Year-over-year growth 2019-2023 (%) Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 35: ROW - Year-over-year growth 2019-2023 (%) Exhibit 36: Key leading countries Exhibit 37: Market opportunity Exhibit 38: Impact of drivers and challenges Exhibit 39: Pipeline for bispecific antibodies for cancer treatment Exhibit 40: Vendor landscape Exhibit 41: Landscape disruption Exhibit 42: Vendors covered Exhibit 43: Vendor classification Exhibit 44: Market positioning of vendors Exhibit 45: Amgen Inc. - Vendor overview Exhibit 46: Amgen Inc. - Product segments Exhibit 47: Amgen Inc. - Organizational developments Exhibit 48: Amgen Inc. - Geographic focus Exhibit 49: Amgen Inc. - Key offerings Exhibit 50: Astella Pharma Inc. - Vendor overview Exhibit 51: Astella Pharma Inc. - Business segments Exhibit 52: Astella Pharma Inc. - Organizational developments Exhibit 53: Astella Pharma Inc. - Key offerings Exhibit 54: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Vendor overview Exhibit 55: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Key offerings Exhibit 56: Merus - Vendor overview Exhibit 57: Merus - Product segments Exhibit 58: Merus - Key offerings Exhibit 59: Regeneron Pharmaceuticals, Inc. - Vendor overview Exhibit 60: Regeneron Pharmaceuticals, Inc. - Business segments Exhibit 61: Regeneron Pharmaceuticals, Inc. - Organizational developments Exhibit 62: Regeneron Pharmaceuticals, Inc. - Key offerings Exhibit 63: Validation techniques employed for market sizing

Amgen Inc. Astella Pharma Inc. Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. Merus Regeneron Pharmaceuticals, Inc.